Association of torsades de pointes with novel and known single nucleotide polymorphisms in long QT syndrome genes

Fermini, 2004, Pre-clinical assessment of drug-induced QT interval prolongation. Current issues and impact on drug discovery, Annu Rep Med Chem, 39, 323, 10.1016/S0065-7743(04)39024-X Khan, 2002, Clinical and therapeutic aspects of congenital and acquired long QT syndrome, Am J Med, 112, 58, 10.1016/S0002-9343(01)01011-7 Strauss, 2006, Prolonged QTc interval and risk of sudden cardiac death in a population of older adults, J Am Coll Cardiol, 47, 362, 10.1016/j.jacc.2005.08.067 Roden, 2004, Drug-induced prolongation of the QT interval, N Engl J Med, 350, 1013, 10.1056/NEJMra032426 Aerssens, 2005, Pharmacogenomics and acquired long QT syndrome, Pharmacogenomics, 6, 259, 10.1517/14622416.6.3.259 Roepke, 2006, Pharmacogenetics and cardiac ion channels, Vasc Pharm, 44, 90, 10.1016/j.vph.2005.07.013 Wang, 1996, Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias, Nature Genetics, 12, 17, 10.1038/ng0196-17 Wang, 1995, SCN5A mutation associated with an inherited cardiac arrhythmia, Cell, 80, 805, 10.1016/0092-8674(95)90359-3 Benson, 1996, Missense mutations in the pore region of HERG causes familial long QT syndrome, Circulation, 93, 1791, 10.1161/01.CIR.93.10.1791 Duggal, 1998, Mutation of the gene for IsK associated with both Jervell and Lange-Nielsen and Romano-Ward forms of long QT syndrome, Circulation, 97, 142, 10.1161/01.CIR.97.2.142 Tester, 2005, Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing, Heart Rhythm, 2, 507, 10.1016/j.hrthm.2005.01.020 Napolitano, 2005, Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice, JAMA, 294, 2975, 10.1001/jama.294.23.2975 Drolet, 1998, Block of the component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug related lengthening of the QT interval, Circulation, 97, 204, 10.1161/01.CIR.97.2.204 Suessbrich, 1997, The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channel expressed in Xenopus oocytes, Br J Pharmacol, 120, 968, 10.1038/sj.bjp.0700989 Paulussen, 2004, Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients, J Mol Med, 82, 182, 10.1007/s00109-003-0522-z Vos, 2004, Genetic basis of drug-induced arrhythmias, Ann Med, 36, S35, 10.1080/17431380410032634 Moller, 2001, Dofetilide in patients with congestive heart failure and left ventricular dysfunction: safety aspects and effect on atrial fibrillation. The Danish Investigators of Arrhythmia and Mortality on Dofetilide (DIAMOND) study group, Congest Heart Fail, 7, 146, 10.1111/j.1527-5299.2001.00243.x Sun, 2004, Role of a KCNH2 polymorphism (R1047L) in dofetilide-induced torsades de pointes, J Mol Cell Cardiol, 37, 1031, 10.1016/j.yjmcc.2004.09.001 Warnes, 2003, The genetics package, R News, 3, 9 Ackerman, 2003, Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome, Mayo Clin Proc, 78, 1479, 10.4065/78.12.1479 Ackerman, 2004, Spectrum and prevalence of cardiac sodium channel variants among black, white, Asian, and Hispanic individuals: implications for arrhythmogenic susceptibility and Brugada/long QT syndrome genetic testing, Heart Rhythm, 1, 600, 10.1016/j.hrthm.2004.07.013 Pfeufer, 2005, Common variants in myocardial ion channel genes modify the QT interval in the general population: results for the KORA study, Circ Res, 96, 693, 10.1161/01.RES.0000161077.53751.e6 Splawski, 2000, Spectrum of mutations in long-QT syndrome genes KVLQT1, HERG, SCN5A, KCNE1, and KCNE2, Circulation, 102, 1178, 10.1161/01.CIR.102.10.1178 Laitinen, 2000, Survey of the coding region of the HERG gene in long QT syndrome reveals six novel mutations and an amino acid polymorphism with possible phenotypic effects, Hum Mutat, 15, 580, 10.1002/1098-1004(200006)15:6<580::AID-HUMU16>3.0.CO;2-0 Paulussen, 2003, Mutation analysis in congenital long QT syndrome—a case with missense mutations in KCNQ1 and SCN5A, Genetic Testing, 7, 57, 10.1089/109065703321560958 Sherman, 2005, Targeted mutational analysis of ankyrin-B in 541 consecutive, unrelated patients referred for long QT syndrome genetic testing and 200 healthy subjects, Heart Rhythm, 2, 1218, 10.1016/j.hrthm.2005.07.026 Moss, 2006, QTc prolongation and sudden cardiac death, J Am Coll Cardiol, 47, 368, 10.1016/j.jacc.2005.10.024 Bezzina, 2003, A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization, Cardiovasc Res, 59, 27, 10.1016/S0008-6363(03)00342-0 Paavonen, 2003, Functional characterization of the common amino acid 897 polymorphism of the cardiac potassium channel KCNH2 (HERG), Cardiovasc Res, 59, 603, 10.1016/S0008-6363(03)00458-9 Gouas, 2005, Association of KCNQ1, KCNE1, KCNH2 and SCN5A polymorphisms with QTc interval length in a healthy population, Eur J Hum Genet, 13, 1213, 10.1038/sj.ejhg.5201489 Yang, 2002, Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes, Circulation, 105, 1943, 10.1161/01.CIR.0000014448.19052.4C Ye, 2003, A common human SCN5A polymorphism modifies expression of an arrhythmia causing mutation, Physiol Genomics, 12, 187, 10.1152/physiolgenomics.00117.2002 Crotti, 2005, KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome, Circulation, 112, 1251, 10.1161/CIRCULATIONAHA.105.549071